^
Association details:
| Biomarker: | RB1 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study
Published date:
05/14/2021
Excerpt:
AR amplification and TP53 and/or RB1 alterations were associated with resistance to abiraterone or docetaxel.
DOI:
10.6004/jnccn.2020.7663
